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Impaired flow-induced arterial remodeling
in DOCA-salt hypertensive rats
Pieter Lemkens1,2, Jelly Nelissen1,2, Merlijn JPMT Meens1, Gregorio E Fazzi1, Ger JM Janssen1,
Jacques JM Debets1, Ben JA Janssen1, Paul MH Schiffers1 and Jo GR De Mey1
Arteries from young healthy animals respond to chronic changes in blood flow and blood pressure by structural remodeling.
We tested whether the ability to respond to decreased (90%) or increased (þ100%) blood flow is impaired during the
development of deoxycorticosterone acetate (DOCA)-salt hypertension in rats, a model for an upregulated endothelin-1 system.
Mesenteric small arteries (MrA) were exposed to low blood flow (LF) or high blood flow (HF) for 4 or 7 weeks. The
bioavailability of vasoactive peptides was modified by chronic treatment of the rats with the dual neutral endopeptidase
(NEP)/endothelin-converting enzyme (ECE) inhibitor SOL1. After 3 or 6 weeks of hypertension, the MrA showed hypertrophic
arterial remodeling (3 weeks: media cross-sectional area (mCSA): 10±1103 to 17±2103 lm2; 6 weeks: 13±2103
to 24±3103 lm2). After 3, but not 6, weeks of hypertension, the arterial diameter was increased (Ø: 385±13 to
463±14 lm). SOL1 reduced hypertrophy after 3 weeks of hypertension (mCSA: 6103±1103lm2). The diameter of the
HF arteries of normotensive rats increased (Ø: 463±22 lm) but no expansion occurred in the HF arteries of hypertensive rats
(Ø: 471±16lm). MrA from SOL1-treated hypertensive rats did show a significant diameter increase (Ø: 419±13 to
475±16 lm). Arteries exposed to LF showed inward remodeling in normotensive and hypertensive rats (mean Ø between 235
and 290 lm), and infiltration of monocyte/macrophages. SOL1 treatment did not affect the arterial diameter of LF arteries but
reduced the infiltration of monocyte/macrophages. We show for the first time that flow-induced remodeling is impaired during
the development of DOCA-salt hypertension and that this can be prevented by chronic NEP/ECE inhibition.
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INTRODUCTION
Blood flow is an important regulator of vascular function and
structure. An acute alteration in blood flow initially leads to a change
in vasomotor tone, which modifies the arterial diameter to normalize
wall shear stress. When the increase in blood flow is sustained, arteries
can structurally remodel to restore normal values of wall shear stress
and circumferential wall stress.1 Both flow-mediated dilatation and
flow-mediated remodeling are endothelium-dependent processes.2,3
Structural remodeling of the arterial wall in response to
hemodynamic changes can occur under both physiological and
pathological conditions, for example, in the uterine vascular bed
during pregnancy and in hypertension, respectively.4–6
Because in established hypertension cardiac output is within the
normal range, the increased blood pressure is mainly due to increased
vascular resistance.7 This is associated with an increased wall to lumen
ratio in the systemic resistance arteries. In essential hypertension, this
arterial remodeling is usually described as inward and eutrophic, that
is, resulting from rearrangement of the medial material around a
smaller diameter.8 The arterial changes in secondary and experimental
hypertension, on the other hand, are mainly hypertrophic in nature
and involve smooth muscle cell hypertrophy and/or hyperplasia.8,9
Remodeling of the vascular wall in hypertension is also associated
with changes in the composition of the extracellular matrix leading to
increased stiffness.10
Although anti-hypertensive therapy is mainly focused on lowering
the blood pressure, preventing or reversing the arterial structural
changes might be more beneficial for the morbidity and mortality of
hypertensive patients.11 Angiotensin II is thought to have an
important role in the pathological alterations in the vascular wall,
as is supported by the partial reversal of these alterations by chronic
treatment with inhibitors of angiotensin-converting enzyme or
antagonists of AT1-receptors.12,13 Endothelin-1 (ET1), another
vasoactive peptide, might also be involved in the arterial structural
changes in pathophysiological conditions. Apart from being a potent
vasoconstrictor, ET1 is also a potent growth-promoting and
proinflammatory agent.14–18 Production of ET1 is reported to be
increased in salt-dependent models of hypertension such as
deoxycorticosterone acetate (DOCA)-salt-induced hypertension, a
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model showing pronounced endothelial dysfunction19 and arterial
hypertrophy.20,21 ET1 can be formed through cleavage of big ET1 by
endothelin-converting enzyme (ECE). Alternatively big ET1 can be
hydrolyzed by chymase or MMP-2 to form ET1 (1-31) or ET1 (1-32),
respectively. Both are further processed into ET1 by neutral
endopeptidase (NEP).22–24 Thus, a dual inhibitor of NEP and ECE
reduces ET1 production by inhibiting all three pathways.25 Recently
Kalk et al.26 reported that the dual NEP/ECE inhibitor SLV338
reduces smooth muscle hypertrophy, interstitial fibrosis and
perivascular fibrosis in the two kidney one clip model, partly by
suppression of TGF-b1 expression.
Here we tested the hypotheses that (1) flow-induced remodeling of
resistance arteries is reduced during the development of DOCA-salt
hypertension and that (2) treatment with a dual NEP/ECE inhibitor
has beneficial effects on flow-induced arterial remodeling in this
setting.
METHODS
Animals, model and surgery
Ten-week-old Wistar rats (Charles River, Maastricht, The Netherlands) were
used in all experiments that were performed in accordance with the ethical
committee for animal welfare of the Maastricht University.
All animals were anesthetized with isoflurane (1–4%) and the left kidney
was removed. Blood flow-modifying surgery was performed in the animals by
distal ligation of alternate first-order mesenteric arteries to create arteries
chronically exposed to low blood flow (LF). The patent arteries between these
then had a compensatory increased blood flow (HF). Arteries from a distant
part of the intestine were considered control arteries exposed to normal flow
(NF).9,27 After a 1-week recovery period, a DOCA pellet (100mg, Sigma
Aldrich, Zwijndrecht, The Netherlands) (n¼ 28) or a control silicon pellet
(n¼ 29) was implanted subcutaneously. All animals were given high-salt
drinking water (1% NaCl and 0.2% KCl). In total, 16 normotensive rats and 14
hypertensive rats were investigated after 3 weeks and 13 normotensive and 14
hypertensive rats after 6 weeks.
Intra-arterial blood pressure was measured in conscious unrestrained rats
via a heparinized (5Uml1) indwelling polyethylene catheter that was
introduced into the left femoral artery 2 days before measurement. The
arterial catheter was connected to a pressure transducer (Micro Switch 150 PC,
Honeywell, Amsterdam, The Netherlands) and its output was sampled at
2.5 kHz. Mean arterial pressure (MAP) was calculated using the IDEEQ data-
acquisition system (Instrument Services, Maastricht University, Maastricht,
The Netherlands).
Preliminary dose-finding experiments were carried out to identify
appropriate doses of the dual NEP/ECE inhibitor SOL1 (2-{[1-({[(3S)-1-
(carboxymethyl-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]amino}carbo-
nyl)cyclopentyl]methyl}-4-[[3-methylamino)propyl](methyl)amino]-4-oxobu-
tanoic acid; Abbott25). A dose of 50mg kg1 per day drastically decreased
urinary ET1 content (from 32.89±3.91 to 1.35±0.25 pgml1, Po0.001) in
DOCA-salt hypertensive rats (n¼ 3). Animals were randomly assigned to the
treatment groups (n¼ 7). Osmotic minipumps (2ML4, Alzet, Cupertino, CA,
USA) were implanted subcutaneously, simultaneously with the DOCA pellet,
for chronic continuous drug treatment over the next 3 weeks. The vehicle
group received osmotic minipumps containing a saline solution for the same
period of time.
Determination of arterial remodeling
Three or 6 weeks after the induction of hypertension, animals were euthanized
with isoflurane (44%) and arteries exposed in vivo to HF or LF conditions
were isolated. Arteries located outside the region of ligation were used as
normal flow controls (NF). Arteries were mounted on two glass micropipettes
in an organ chamber filled with Ca2þ -free Krebs Ringer solution (144mM
NaCl, 4.7mM KCl, 1.2mM MgSO4, 1.2mM KH2PO4, 14.9mM HEPES and
5.5mM glucose; pH 7.4). Ten micromolar Na-nitroprusside (SNP, Sigma
Aldrich) was added to ensure maximal vasodilatation. A pressure–diameter
relationship was established by recording the lumen diameter while gradually
increasing the distending pressure (20–120mmHg, 10mmHg steps). After the
experiment, vessels were fixed at 80mmHg in 4% phosphate-buffered
formaldehyde solution for 1 h and stored in 70% ethanol.
Arterial distensibility was calculated by: DC¼ (1/DP) (DD/Dn1) 100
with DC¼ distensibility, P¼ intraluminal pressure and D¼measured
diameter.28 A linear regression was performed on the pressure–distensibility
curves between 20 and 80mmHg for every artery considered and the slope was
calculated as an index of arterial stiffness.
Histological analyses
Fixed vessels were embedded in paraffin and cross-sections (4mm) were stained
with Lawson’s solution (Boom, Meppel, The Netherlands). Media cross-
sectional area (mCSA) was determined from the circumferences of the internal
and external elastic laminae. The average number of nuclear profiles in the
media was determined by counting on haematoxylin–eosin-stained cross-
sections (# nuclei). The elastin density was determined in four areas of the
media and four areas of the adventitia in every vessel using Leica Qwin
software (Leica, Groot Bijgaarden, Belgium). Measurements were averaged for
every layer individually in every vessel. Elastin content was calculated as
percentage elastin-positive area per total area. To stain collagen, cross-sections
were deparaffinized and incubated in phosphomolybdenic acid (0.2%) for
5min, followed by incubation with Sirius red. After washing with 0.1M HCl for
2min, sections were dehydrated and protected with coverslips. The content of
collagen in the media and adventitia was quantified as described as for elastin.
To identify smooth muscle cells and monocyte/macrophages, immunoper-
oxidase staining was performed with primary monoclonal antibodies directed
against smooth muscle a-actin and rat monocyte/macrophages, respectively
(ASMA (A-2547) and CD-68 (ED-1).29 (Sigma Aldrich, dilution 1:5000). After
incubation with these monoclonal antibodies, the sections were incubated with
peroxidase-conjugated rabbit anti-mouse immunoglobulins (Dako, Enschede,
The Netherlands). Visualization was performed with DAB as a substrate.
Statistical analysis
Results are expressed as means±s.e.m. Statistical significance of differences
between groups was evaluated by analysis of variance (ANOVA for consecutive
measurements for pressure–diameter curves) or one-way ANOVA followed by
Bonferroni or paired t-test (graphpad 5.0). A value of Po0.05 was considered
statistically significant.
RESULTS
General characteristics
In normotensive rats, body weight and MAP did not change
significantly between 14 and 17 weeks of age (Table 1). DOCA-salt
treatment did not modify body weight but increased MAP after 3
weeks and to a greater extent after 6 weeks (Table 1). Administration
of the dual NEP/ECE inhibitor SOL1 (50mg kg1 per day) to DOCA-
salt rats for 3 weeks did not modify body weight but attenuated the
increase in MAP (Table 1).
In normotensive rats, the size of mesenteric small arteries (MrA)
tended to increase between 14 and 17 weeks of age (Figures 1a,b and 2).
The increases in lumen diameter (Ø: 385±13 to 414±20mm) in
mCSA (10±1 to 13±2 103mm2) and in the number of nuclear
profiles per medial section (# nuclei: 45±3 to 49±5) did, however,
not reach statistical significance.
Resistance artery remodeling in DOCA-salt hypertensive rats
MrA diameter was significantly increased after 3 weeks of DOCA-salt
hypertension (Ø: 385±13 to 452±12mm, Po0.05; Figures 1c and
2a). After 6 weeks of hypertension, MrA diameter tended to be
increased (Ø: 414±20 to 451±12mm; Figures 1d and 2b) but this
was no longer statistically significant compared with arteries
from age-matched normotensive rats. After both 3 and 6 weeks of
DOCA-salt hypertension, significant media hypertrophy was observed
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(mCSA: 3 weeks: 10±1 to 16±1 103mm2, Po0.01; 6 weeks: 13±2
to 24±3 103mm2, Po0.01; Figures 2c and d). This was accom-
panied by hyperplasia and by increased arterial wall stiffness. # nuclei
averaged 45±3 and 58±4 at 3 weeks (Po0.05; Figure 2e) and 49±5
and 66±7 at 6 weeks (nonsignificant (NS); Figure 2f) and the stiffness
factor averaged 0.034±0.002 and 0.022±0.002 mmHg2 at
3 weeks (Figure 2g) and 0.031±0.002 and 0.016±0.002 mmHg2
at 6 weeks (Figure 2h) in normotensive and hypertensive rats,
respectively. The elastin to collagen ratio was, however, neither
significantly modified (Table 1) nor there was a significant increase in
monocyte/macrophages in the tunica media of MrA from DOCA-salt
hypertensive rats (Table 1).
Three weeks treatment of DOCA-salt hypertensive rats with SOL1
tended to attenuate arterial outward remodeling (Ø: 419±13mm, NS,
Figures 1e and 2a), but did not modify arterial hypertrophy (mCSA:
14±2 103mm2, Figure 2c), arterial stiffness (0.021±0.002 mmHg2,
Figure 2g) or elastin to collagen ratio (0.81±0.47). Chronic treatment
with the dual NEP/ECE inhibitor did, however, significantly reduce
arterial hyperplasia (# nuclei: 42±3, Po0.05 vs. solvent-treated
DOCA-salt rats) (Figure 2e).
Flow-related arterial remodeling in normotensive rats
Increased local blood flow (HF) for 4 weeks in normotensive rats
caused an upward shift of the pressure–diameter relationship
(Figure 1a) and significantly increased lumen diameter (Ø: to
463±22mm, Po0.001; Figure 2a), medial mass (mCSA: to 15±2
103mm2, Po0.05; Figure 2c) and cellularity at 80mmHg (# nuclei: to
56±3; Figure 2e) compared with vessels exposed to normal blood
flow (NF). This is in line with the flow-induced outward hypertrophic
remodeling reported previously.9,27,30,31 It was, however, not
accompanied by alterations in arterial wall stiffness (Figure 2g), the
elastin to collagen ratio or the macrophage count (Table 1). Surpris-
ingly, after 7 weeks exposure to elevated blood flow, the outward
remodeling (Figure 1b) and the increases in lumen diameter (Ø: to
455±21mm, NS, Figure 2b), in medial mass (mCSA: to 14±1
103mm2, NS, Figure 2d) and the hyperplasia (# nuclei: to 41±3, NS;
Figure 2f), were no longer statistically significant compared with
control (NF) arteries of the same normotensive rats.
Reduced local blood flow (LF) for either 4 or 7 weeks in
normotensive rats markedly reduced arterial diameter and markedly
increased arterial wall stiffness (Figures 1a,b and 2a,b,g,h) without
Table 1 General animal characteristics and overview of structural parameters
3 Weeks 6 Weeks
General characteristics NT HT HTþSOL1 NT HT
Body weight (g) 353±6 331±6 359±9 368±12 338±8
MAP (mm Hg) 118±2 150±5*** 136±2& 114±3 173±3***
Diameter (mm)
Normal flow 385±13 452±12* 419±13 414±20 451±12
High flow 463±22### 471±16 475±16# 455±21 486±12
Low flow 270±10### 290±14### 253±6### 265±14### 265±14###
mCSA (103mm2)
Normal flow 10±1 16±1** 14±2 13±2 24±3*
High flow 15±2# 16±1 14±2 14±1 21±2
Low flow 11±3 12±2# 7±1& 11±3 16±2
# Nuclear profiles (media)
Normal flow 45±3 58±4 42±3& 49±5 66±7
High flow 56±3# 53±5 45±4 41±3 53±4
Low flow 65±8# 57±9 42±4 40±4 90±13
Stiffness factor (mmHg2)
Normal flow 0.034±0.002 0.022±0.002*** -0.021±0.002 -0.031±0.002 -0.016±0.002***
High flow 0.031±0.002 0.018±0.002*** 0.019±0.002 0.027±0.003 0.017±0.002**
Low flow 0.003±0.001### 0.004±0.001### 0.002±0.001### 0.006±0.001### 0.001±0.001###
Elastin/collagen ratio
Normal flow 2.7±0.8 1.3±0.5 0.8±0.5 5,7±2.3 1.8±0.3
High flow 2.1±0.5 2.0±0.7 3.5±1.2 2.74±0.6 1.8±0.5
Low flow 9.1±6.3 1.3±0.4 2.8±1.1 4.0±0.9 6.0±3.0#
% ED-1-positive area
Normal flow 0.02±0.01 0.17±0.11 0.08±0.02 0.03±0.01 0.02±0.01
High flow 0.03±0.01 0.29±0.11 0.11±0.05 0.01±0.01 0.03±0.01
Low flow 1.24±0.56# 5.89±3.10## 0.24±0.09& 0.38±0.23 1.41±0.63#
Abbreviations: HT, deoxycorticosterone acetate (DOCA)-salt hypertensive rats; MAP, mean arterial pressure; mCSA, media cross-sectional area; NT, normotensive rats; SOL1,
(2-{[1-({[(3S)-1-(carboxymethyl-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]amino}carbonyl)cyclopentyl]methyl}-4-[[3-methylamino)propyl](methyl)amino]-4-oxobutanoic acid.
Data are shown as mean±s.e.m.
*Po0.05; **Po0.01; ***Po0.001 NT vs. HT; #Po0.05; ###Po0.001 vs. NF; &Po0.05 HT vs. HTþSOL1.
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significant changes in medial mass (mCSA: to 11±1 and 11±3
103mm2, NS, Figures 2c and d) or medial cell number (# nuclei:
40±4 and 90±13, after 4 and 7 weeks, respectively, NS, Figures 2e
and f). At 3 weeks an elevated number of ED-1-positive monocyte/
macrophages was observed in the LF vessels of normotensive rats, but
this was no longer statistically significant at the later time point
(Table 1).
Flow-related arterial remodeling in DOCA-salt hypertensive rats
In MrA of DOCA-salt hypertensive rats, no additional outward
hypertrophic remodeling occurred in HF arteries after 4 weeks (Ø:
452±12 to 471±16mm, mCSA: 16±1 to 16±1 103mm2, # nuclei:
53±4 to 53±5) (Figures 1c and 2a,c,e) and after 7 weeks (Ø:
451±12 to 486±12mm, mCSA: 24±3 to 21±2 103mm2, # nuclei:
66±7 to 53±4) (Figures 1d and 2b,d,f). Flow-induced outward
remodeling was, however, improved by 3 weeks treatment with SOL1
(Ø: from 419±13 to 475±16mm, Po0.05; Figures 1e and 2a) but no
hypertrophy was found in HF arteries of DOCA-salt hypertensive
rats treated with SOL1 (mCSA from 14±2 to 14±2 103 mm2)
(Figure 2c).
Although additional outward remodeling was blunted in DOCA-
salt hypertensive rats, their LF arteries became markedly narrower
(Figures 1c,d and 2a,b) and stiffer (Figures 2g and h). Lumen
diameter was reduced from 452±12 to 290±14mm (Po0.001) and
from 451±16 to 265±14mm (Po0.001) at 3 and 6 weeks of
hypertension, respectively (Figure 2). Media mass was significantly
reduced at 3 weeks (mCSA: 16±1 to 12±2 103mm2, Po0.05) but
not at 6 weeks of hypertension (mCSA: 24±3 to 16±2 103mm2,
NS; Figure 2), a stage at which a marked increase in medial cell
number was observed (Figure 2f). Despite the marked stiffening, the
elastin to collagen ratio was significantly increased (Table 1).
Chronic treatment of DOCA-salt hypertensive rats with the dual
NEP/ECE inhibitor SOL1 further decreased the diameter of LF
arteries (Ø: 253±6mm) and significantly decreased their mCSA
(7±1 103mm2, Po0.05) and medial cell number (# nuclei: 42±4)
but did not affect stiffness (Figure 2) or elastin/collagen (Table 1).
Figure 1 Relation between imposed pressure and diameter after 4 weeks of altered flow in mesenteric resistance arteries of (a) normotensive rats (NT),
(c) DOCA-salt hypertensive rats (HT) and (e) HTþSOL1. Relation between imposed pressure and diameter after 7 weeks of altered flow in mesenteric
resistance arteries in (b) NT and (d) HT. Data are shown as mean±s.e.m. Normal flow, high flow, low flow: arteries that had been exposed to normal,
increased and reduced blood flow in vivo, respectively.
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In an attempt to evaluate inflammation and characterize the nature
of the hyperplastic changes, we performed immunohistochemistry for
ED-1 and smooth muscle a-actin (ASMA) (Figure 3). Significant
numbers of monocyte/macrophages in the tunica media were
observed only in LF arteries (Table 1). In arteries of normotensive
rats this was a transient response, whereas in arteries of DOCA-salt
hypertensive rats this was still statistically significant at 6 weeks
(Table 1). Treatment with SOL1 significantly reduced this index of
inflammation (Table 1). ED-1 staining was also observed in the
adventitia of LF arteries (Figure 3b), but this could not be crisply
quantified. ASMA staining indicates that the vast majority of cells in
the hyperplastic tunica media of the LF arteries of DOCA-salt
hypertensive rats were still differentiated smooth muscle cells
(Figure 3d). Moreover, this approach revealed development of new
blood vessels in this setting.
DISCUSSION
The main findings of this study are that in mesenteric resistance
arteries of DOCA salt hypertensive rats flow-induced outward
remodeling is impaired. Moreover, the mesenteric resistance arteries
of DOCA-salt hypertensive rats are hypertrophic and show a clear
inflammatory component. These effects can partly be prevented by
treatment with a dual NEP/ECE inhibitor.
DOCA-salt hypertension is a model of low renin/angiotensin but
high ET1 levels that shows pronounced endothelial dysfunction19 and
arterial hypertrophy.20,21 ET1 is not only a potent vasoconstrictor;14
it is also a proinflammatory agent,17 has mitogenic effects on vascular
smooth muscle cells,15 is pro-angiogenic18 and promotes fibrosis.16
An upregulation of the ET1 system has been linked to numerous
pathologies, including salt-sensitive hypertension.20,21,32,33 Because of
these functions the endothelin system might in large part contribute
to the hypertrophy and the endothelial dysfunction observed in
DOCA-salt hypertension. In an attempt to test this we (i) treated
DOCA-salt hypertensive rats for 3weeks with the NEP/ECE inhibitor
SOL1 and (ii) studied the endothelium-dependent structural effects of
imposed changes in blood flow in DOCA salt hypertensive rats.
In this study MrA’s of DOCA-salt hypertensive rats showed
hypertrophic arterial remodeling after 3 and 6 weeks. At 3 weeks of
Figure 2 The lumen diameter as measured at 80 mmHg after (a) 4 and (b) 7 weeks of altered blood flow. The effect of altered blood flow on cross-sectional
area of the medial layer after (c) 4 and (d) 7 weeks. The effect of altered blood flow on the number of medial cells per cross-section after (e) 4 and (f) 7
weeks. The effect of altered blood flow on the stiffness index after (g) 4 and (h) 7 weeks. Data are shown as mean±s.e.m. *Po0.05, **Po0.01,
***Po0.001 normotensive rats (NT) vs. DOCA-salt hypertensive rats (HT); #Po0.05, ###Po0.001 vs. NF, &Po0.05 HT vs. HTþSOL1. mCSA: cross-
sectional area of the medial layer; NF, HF, LF: arteries that had been exposed to normal, increased and reduced blood flow in vivo, respectively.
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hypertension an increase in diameter was observed whereas at 6 weeks
of hypertension diameter did not differ from that in arteries of
normotensive rats that had increased as a result of development.
Reports from other groups lean more to an unaltered or decreased
arterial diameter.5,21 This discrepancy might be because of differences
in strain and age of the rats and in other aspects of the protocols used
to induce DOCA-salt hypertension. A possible explanation for the
increase in diameter after 3 weeks of hypertension is that in this
experimental model blood pressure rises in a much shorter timeframe
than in genetic hypertension8 and that mesenteric blood flow may
increase during the first weeks of DOCA-salt hypertension.34
Although outward remodeling is generally not observed in models
of hypertension, hypertrophic remodeling is often witnessed especially
in models of non genetic hypertension and experimental
hypertension. Also ET1 has been shown to contribute to the
remodeling of large and small arteries in hypertension.35,36
Hypertrophic remodeling rather than eutrophic remodeling of
resistance arteries seems to occur in models associated with an
upregulated endothelin system.5 This is in line with the observation
that chronic administration of the non- selective ET-receptor
antagonist bosentan reduces the cross-sectional area of the arterial
media in DOCA-salt hypertensive rats.5 In contrast in mRen2
transgenic rats, a model of enhanced endogenous angiotensin II
generation, inward eutrophic remodeling was observed, and bosentan
had no effects on arterial structure.37 A dual ACE/NEP inhibitor and
an ACE inhibitor on the other hand caused a significant regression of
arteriolar structural changes.38–40 Figure 4 shows a schematic over-
view of changes in arterial lumen diameter and medial mass in
relation to hypertension (blue arrow) and age (purple arrow).
In the present study, 3 week treatment of DOCA-salt hypertensive
rats with the NEP/ECE inhibitor SOL1 tended to reduce the
arterial diameter and hypertrophy, and significantly reduced
the arterial hyperplasia. Whether this is due to reduction of the
direct arterial effects of ET1 or indirectly to the reduction of blood
pressure, however, remains to be established. To discriminate between
the effects of blood pressure lowering and of modified levels of
vasoactive peptides, future studies with vasodilator compounds in a
setting similar to the one used here may be considered. Figure 4
shows a schematic overview of changes in arterial lumen diameter and
medial mass in relation to SOL1 treatment during hypertension
(orange arrow).
Pourageaud and De Mey showed that in 6-week-old Wistar-Kyoto
rats elevated blood flow resulted in outward hypertrophic remodeling
and reduced blood flow in inward hypotrophic remodeling 4 weeks
after flow altering surgery.30 Similar observations were made by our
group and others.27,30,41,42 In the present study, we observed flow-
induced outward hypertrophic remodeling but no hypotrophy in
resistance arteries exposed to low blood flow in normotensive Wistar
rats studied between 10 and 14 weeks of age. This indicates
dependence of flow-related arterial remodeling on rat age43 and
strain.44 Unexpectedly, no significant differences in diameter and
media mass were observed between control arteries and arteries
Figure 3 Cross-sections of low-flow arteries of normotensive rats stained for (a) ED-1 and (c) a-smooth muscle actin, and DOCA-salt hypertensive rats
stained for (b) ED-1 and (d) a-smooth muscle actin.
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exposed to elevated blood flow for 7 weeks in normotensive rats. This
seems to be due to the growth and development of the control arteries
during this period time. We speculate in this respect that the marked
flow-induced remodeling of young arteries represents an accelerated
developmental process.45
In resistance arteries of DOCA-salt hypertensive rats, remodeling in
response increased blood flow was blunted (see below) but structural
responses to reduced blood flow were extensive. We observed a
marked decrease in diameter that was, as in normotensive rats, not
accompanied by a significant change in media mass. Unlike in
normotensive rats, signs of marked and long-lasting inflammation
were observed such as extensive ED-1 staining in tunica media and
adventitia, and sprouting of new vessels in the adventitial layer. The
observation that in DOCA-salt hypertensive rats treated with SOL1,
mesenteric arteries exposed to decreased flow were hypotrophic and
lack the inflammatory component, as well as the artery-like structures
in the adventitia are in line with the mitogenic, proinflammatory and
proangiogenic effects of ET1.15,17,18
Flow-induced outward arterial remodeling did not occur in
DOCA-salt hypertensive rats. This implies that the physiological
response to an increase in flow, outward remodeling, is impaired in
DOCA-salt hypertensive rats. This model of hypertension is described
to show pronounced endothelial dysfunction19 as evidenced by
increased infiltration of inflammatory cells and reduced endothelium-
dependent vasodilatation and increased endothelium-dependent
vasoconstriction. Several studies indicate a strong interplay between
ET1 and endothelium derived nitric oxide.46 Amiri et al.35 showed
that overexpressing the human prepoET1 gene in the endothelium in
mice caused endothelial dysfunction and reduced NO bioavailability.
Strong evidence indicates that endothelium-derived NO and other
relaxing factors can be released from the endothelium in response to
increased shear stress mediating flow-induced vasodilatation.2,3
Endothelium-derived NO also has a role in the arterial remodeling
of large conduit arteries in response to a chronic increase in blood
flow.47,48 In small resistance-sized arteries, the situation is less clear.
Here NO is not the only endothelium-derived relaxing factor49 and
chronic pharmacological inhibition of NO synthases does not inhibit
flow-induced arterial remodeling.27 In contrast to L-NAME-induced
hypertension, flow-induced remodeling was inhibited in DOCA-salt
hypertensive rats. This indicates that in DOCA-salt hypertension
endothelium-dependent remodeling of resistance arteries is blunted
independently from classical endothelial dysfunction. Outward
remodeling might be independent of endothelium-dependent
vasodilatation. Alternatively, the endothelial dysfunction in DOCA-
salt hypertension might not be restricted to reduced bioavailability of
NO and upregulation of ET1, but also involve another endothelium-
derived relaxing factor such as EDHF contributing to structural
changes. Another possibility is that due to the increase in diameter
occurring during the development of the hypertension and due to the
increased arterial stiffness, the dynamic range to respond to an
imposed increase in flow might be considerably reduced in DOCA-
salt hypertensive rats. Chronic SOL1 treatment during the
development of DOCA-salt hypertension preserved the flow-
induced outward remodeling response. Thus, NEP/ECE inhibition
improves endothelium-dependent structural responses in mesenteric
arteries of DOCA-salt hypertensive rats. Because a moderate
inflammatory response seems necessary for the initiation of
outward remodeling, the pharmacological effect is unlikely due to
its anti-inflammatory consequences. The possible contributions of
reduced blood pressure, reduced synthesis of ET1 and improved non-
NO-mediated relaxation, however, remain to be established. Figure 4
shows a schematic overview of changes in arterial lumen diameter and
medial mass in relation to an increase (green arrows) and a decrease
(red arrows).
Our study has a number of limitations. The three-dimensional-
dissector technique is more accurate to determine changes in cell
number and size than the more rapid counting of nuclear profiles on
hematoxylin–eosin-stained tissue sections.9 Additional measurement
of local transmural pressure and local blood flow at the various time
points would have allowed to speculate on the extent to which
normalization of wall stress and wall shear stress is impaired in
mesenteric resistance arteries of DOCA-salt hypertensive rats.
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Figure 4 Schematic overview of changes in arterial lumen diameter and medial mass in relation to hypertension (blue arrow), imposed changes in flow
(green arrow (high flow) and red arrow (low flow)), SOL1 treatment during hypertension (HTþSOL-1: orange arrow) and age (purple arrow). NT:
normotensive rats, HT: DOCA-salt hypertensive rats.
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In conclusion, in the resistance arteries of DOCA-salt hypertensive
rats, we observed a selective reduction of flow-induced outward
remodeling. This indicates that in this experimental model of
hypertension, endothelial dysfunction is not limited to reduced
endothelium-dependent vasodilatation. In addition some of our
findings in the arteries of both normotensive and hypertensive rats
suggest that experimentally induced and developmental flow-induced
arterial remodeling have the same upper limit. This should be taken
into account when, for instance, vasodilator therapies are being
proposed for the reversal of inward arterial remodeling in essential
hypertension.50
ACKNOWLEDGEMENTS
This study was performed within the framework of the Dutch Top Institute
Pharma project: T2-108; Metalloproteases and Novel Targets in Endothelial
Dysfunction.
1 Martinez-Lemus LA, Hill MA, Meininger GA. The plastic nature of the vascular wall: a
continuum of remodeling events contributing to control of arteriolar diameter and
structure. Physiology 2009; 24: 45–57.
2 Bellien J, Iacob M, Gutierrez L, Isabelle M, Lahary A, Thuillez C, Joannides R. Crucial
role of NO and endothelium-derived hyperpolarizing factor in human sustained conduit
artery flow-mediated dilatation. Hypertension 2006; 48: 1088–1094.
3 Sun D, Huang A, Yan EH, Wu Z, Yan C, Kaminski PM, Oury TD, Wolin MS, Kaley G.
Reduced release of nitric oxide to shear stress in mesenteric arteries of aged rats. Am J
Physiol Heart Circ Physiol 2004; 286: H2249–H2256.
4 Hilgers RH, Schiffers PM, Aartsen WM, Fazzi GE, Smits JF, De Mey JG. Tissue
angiotensin-converting enzyme in imposed and physiological flow-related arterial
remodeling in mice. Arterioscler Thromb Vasc Biol 2004; 24: 892–897.
5 Li JS, Lariviere R, Schiffrin EL. Effect of a nonselective endothelin antagonist on
vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for
a role of endothelin in vascular hypertrophy. Hypertension 1994; 24: 183–188.
6 Jaeckel M, Simon G. Altered structure and reduced distensibility of arteries in Dahl
salt-sensitive rats. J Hypertens 2003; 21: 311–319.
7 Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1982; 62:
347–504.
8 Heagerty AM, Aalkjaer C, Bund SJ, Korsgaard N, Mulvany MJ. Small artery structure
in hypertension. Dual processes of remodeling and growth. Hypertension 1993; 21:
391–397.
9 Buus CL, Pourageaud F, Fazzi GE, Janssen G, Mulvany MJ, De Mey JG. Smooth muscle
cell changes during flow-related remodeling of rat mesenteric resistance arteries. Circ
Res 2001; 89: 180–186.
10 Briones AM, Arribas SM, Salaices M. Role of extracellular matrix in vascular
remodeling of hypertension. Curr Opin Nephrol Hypertens 2010; 19: 187–194.
11 Rizzoni D, Muiesan ML, Porteri E, De Ciuceis C, Boari GE, Salvetti M, Paini A, Rosei EA.
Vascular remodeling, macro- and microvessels: therapeutic implications. Blood Press
2009; 18: 242–246.
12 Rizzoni D, Porteri E, Piccoli A, Castellano M, Bettoni G, Muiesan ML, Pasini G, Guelfi
D, Mulvany MJ, Agabiti Rosei E. Effects of losartan and enalapril on small artery
structure in hypertensive rats. Hypertension 1998; 32: 305–310.
13 Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and
endothelial dysfunction in human essential hypertension by the angiotensin receptor
antagonist losartan. Circulation 2000; 101: 1653–1659.
14 Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y,
Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular
endothelial cells. Nature 1988; 332: 411–415.
15 Donckier JE, Michel L, Van Beneden R, Delos M, Havaux X. Increased expression of
endothelin-1 and its mitogenic receptor ETA in human papillary thyroid carcinoma.
Clin Endocrinol 2003; 59: 354–360.
16 Ammarguellat F, Larouche I, Schiffrin EL. Myocardial fibrosis in DOCA-salt hyperten-
sive rats: effect of endothelin ET(A) receptor antagonism. Circulation 2001; 103:
319–324.
17 Saleh MA, Boesen EI, Pollock JS, Savin VJ, Pollock DM. Endothelin-1 increases
glomerular permeability and inflammation independent of blood pressure in the rat.
Hypertension 2010; 56: 942–949.
18 Boldrini L, Pistolesi S, Gisfredi S, Ursino S, Ali G, Pieracci N, Basolo F, Parenti G,
Fontanini G. Expression of endothelin 1 and its angiogenic role in meningiomas.
Virchows Arch 2006; 449: 546–553.
19 Schiffrin EL. Vascular endothelin in hypertension. Vascul Pharmacol 2005; 43:
19–29.
20 Schiffrin EL, Lariviere R, Li JS, Sventek P, Touyz RM. Deoxycorticosterone acetate plus
salt induces overexpression of vascular endothelin-1 and severe vascular hypertrophy in
spontaneously hypertensive rats. Hypertension 1995; 25(Part 2): 769–773.
21 Schiffrin EL, Lariviere R, Li JS, Sventek P, Touyz RM. Endothelin-1 gene expression
and vascular hypertrophy in DOCA-salt hypertension compared to spontaneously
hypertensive rats. Clin Exp Pharmacol Physiol Suppl 1995; 22: S188–S190.
22 Sawamura T, Kimura S, Shinmi O, Sugita Y, Yanagisawa M, Goto K, Masaki T.
Purification and characterization of putative endothelin converting enzyme in bovine
adrenal medulla: evidence for a cathepsin D-like enzyme. Biochem Biophys Res
Commun 1990; 168: 1230–1236.
23 Nakano A, Kishi F, Minami K, Wakabayashi H, Nakaya Y, Kido H. Selective
conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-
length endothelins by chymase from human mast cells. J Immunol 1997; 159:
1987–1992.
24 Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2
cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999; 85:
906–911.
25 Nelissen J, Lemkens P, Sann H, Bindl M, Bassissi F, Jasserand D, De Mey JG, Janssen BJ.
Pharmacokinetic and pharmacodynamic properties of SOL1: a novel dual inhibitor
of neutral endopeptidase and endothelin converting enzyme. Life Sci (e-pub ahead of
print 17 February 2012).
26 Kalk P, Sharkovska Y, Kashina E, von Websky K, Relle K, Pfab T, Alter M, Guillaume P,
Provost D, Hoffmann K, Fischer Y, Hocher B. Endothelin-converting enzyme/neutral
endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood
pressure-independent manner. Hypertension 2011; 57: 755–763.
27 Ceiler DL, De Mey JG. Chronic N(G)-nitro-L-arginine methyl ester treatment does not
prevent flow-induced remodeling in mesenteric feed arteries and arcading arterioles.
Arterioscler Thromb Vasc Biol 2000; 20: 2057–2063.
28 Ceiler DL, Nelissen-Vrancken HJ, Smits JF, De Mey JG. Pressure but not angiotensin II-
induced increases in wall mass or tone influences static and dynamic aortic
mechanics. J Hypertens 1999; 17: 1109–1116.
29 Dijkstra CD, Dopp EA, Joling P, Kraal G. The heterogeneity of mononuclear phagocytes
in lymphoid organs: distinct macrophage subpopulations in the rat recognized by
monoclonal antibodies ED1, ED2 and ED3. Immunology 1985; 54: 589–599.
30 Pourageaud F, De Mey JG. Structural properties of rat mesenteric small arteries after
4-wk exposure to elevated or reduced blood flow. Am J Physiol 1997; 273(Part 2):
H1699–H1706.
31 Unthank JL, Nixon JC, Burkhart HM, Fath SW, Dalsing MC. Early collateral and
microvascular adaptations to intestinal artery occlusion in rat. Am J Physiol 1996;
271(Part 2): H914–H923.
32 Hynynen MM, Khalil RA. The vascular endothelin system in hypertension–recent
patents and discoveries. Recent Pat Cardiovasc Drug Discov 2006; 1: 95–108.
33 Dhaun N, Goddard J, Kohan DE, Pollock DM, Schiffrin EL, Webb DJ. Role
of endothelin-1 in clinical hypertension: 20 years on. Hypertension 2008; 52:
452–459.
34 Shimamoto H, Iriuchijima J. Hemodynamic characteristics of conscious deoxycorti-
costerone acetate hypertensive rats. Jpn J Physiol 1987; 37: 243–254.
35 Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM, Reudelhuber TL,
Schiffrin EL. Endothelium-restricted overexpression of human endothelin-1 causes
vascular remodeling and endothelial dysfunction. Circulation 2004; 110: 2233–2240.
36 Fukuda G, Khan ZA, Barbin YP, Farhangkhoee H, Tilton RG, Chakrabarti S. Endothelin-
mediated remodeling in aortas of diabetic rats. Diabetes Metab Res Rev 2005; 21:
367–375.
37 Rossi GP, Sacchetto A, Rizzoni D, Bova S, Porteri E, Mazzocchi G, Belloni AS,
Bahcelioglu M, Nussdorfer GG, Pessina AC. Blockade of angiotensin II type 1 receptor
and not of endothelin receptor prevents hypertension and cardiovascular disease in
transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms.
Arterioscler Thromb Vasc Biol 2000; 20: 949–956.
38 Rossi GP, Bova S, Sacchetto A, Rizzoni D, Agabiti-Rosei E, Neri G, Nussdorfer GG,
Pessina AC. Comparative effects of the dual ACE-NEP inhibitor MDL-100,240 and
ramipril on hypertension and cardiovascular disease in endogenous angiotensin II-
dependent hypertension. Am J Hypertens 2002; 15(2 Part 1): 181–188.
39 Rossi GP, Cavallin M, Rizzoni D, Bova S, Mazzocchi G, Agabiti-Rosei E, Nussdorfer GG,
Pessina AC. Dual ACE and NEP inhibitor MDL-100,240 prevents and regresses severe
angiotensin II-dependent hypertension partially through bradykinin type 2 receptor.
J Hypertens 2002; 20: 1451–1459.
40 Rizzoni D, Rossi GP, Porteri E, Sticchi D, Rodella L, Rezzani R, Sleiman I, De Ciuceis C,
Paiardi S, Bianchi R, Nussdorfer GG, Agabiti-Rosei E. Bradykinin and matrix
metalloproteinases are involved the structural alterations of rat small resistance
arteries with inhibition of ACE and NEP. J Hypertens 2004; 22: 759–766.
41 Tulis DA, Unthank JL, Prewitt RL. Flow-induced arterial remodeling in rat mesenteric
vasculature. Am J Physiol 1998; 274(3 Part 2): H874–H882.
42 Tuttle JL, Nachreiner RD, Bhuller AS, Condict KW, Connors BA, Herring BP, Dalsing MC,
Unthank JL. Shear level influences resistance artery remodeling: wall dimensions,
cell density, and eNOS expression. Am J Physiol Heart Circ Physiol 2001; 281:
H1380–H1389.
43 Miyashiro JK, Poppa V, Berk BC. Flow-induced vascular remodeling in the rat carotid
artery diminishes with age. Circ Res 1997; 81: 311–319.
44 Ibrahim J, Miyashiro JK, Berk BC. Shear stress is differentially regulated among inbred
rat strains. Circ Res 2003; 92: 1001–1009.
45 Glagov S, Vito R, Giddens DP, Zarins CK. Micro-architecture and composition of artery
walls: relationship to location, diameter and the distribution of mechanical stress.
J Hypertens Suppl 1992; 10: S101–S104.
46 Hilgers RH, De Mey JG. Myoendothelial coupling in the mesenteric arterial bed;
segmental differences and interplay between nitric oxide and endothelin-1. Br J
Pharmacol 2009; 156: 1239–1247.
Flow-induced remodeling in DOCA-salt hypertension
P Lemkens et al
1100
Hypertension Research
47 Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS, Sessa WC. Direct evidence for
the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin
Invest 1998; 101: 731–736.
48 Tronc F, Wassef M, Esposito B, Henrion D, Glagov S, Tedgui A. Role of NO in flow-
induced remodeling of the rabbit common carotid artery. Arterioscler Thromb Vasc Biol
1996; 16: 1256–1262.
49 Shimokawa H, Yasutake H, Fujii K, Owada MK, Nakaike R, Fukumoto Y, Takayanagi T,
Nagao T, Egashira K, Fujishima M, Takeshita A. The importance of the hyperpolarizing
mechanism increases as the vessel size decreases in endothelium-dependent relaxa-
tions in rat mesenteric circulation. J Cardiovasc Pharmacol 1996; 28: 703–711.
50 Mulvany MJ. Small artery remodeling and significance in the development of
hypertension. News Physiol Sci 2002; 17: 105–109.
Flow-induced remodeling in DOCA-salt hypertension
P Lemkens et al
1101
Hypertension Research
